TACE delivers a powerful, one-two punch to liver tumors. First, it sends chemotherapy directly into the tumor. Second, it blocks the blood vessel feeding the mass, trapping the medicine inside and starving the tumor of oxygen.
About this scan
Common Indications for TACE
Your doctor may recommend TACE if you have:
- Primary liver cancer (Hepatocellular Carcinoma).
- Cancer that has spread (metastasized) to the liver from the colon, breast, or pancreas.
- Liver tumors that cannot be safely removed with surgery.
What is "Post-Embolization Syndrome"?
Because the tumor is actively breaking down after the blood supply is cut off, most patients experience a set of symptoms called Post-Embolization Syndrome. For a few days, you may feel very tired, have a low-grade fever, experience nausea, and have pain in your upper right abdomen. This is a totally normal and expected reaction, and you will be given medications to manage the pain and nausea.
Before your appointment
Do I need to prepare?
Follow the sedation team's fasting instructions. Assessment includes liver reserve, kidney function, blood count and coagulation, vascular anatomy, portal-vein status, infection, tumor burden, and overall performance; normal tests do not eliminate risk.
During the scan
What happens during the procedure?
The doctor guides a catheter into selected hepatic arteries and delivers chemotherapy with embolic material. Treatment is concentrated in the liver but is not completely confined to the tumor, and systemic and nontarget effects can occur.
Safety and special situations
What are the important limitations and safety checks?
Interventional radiology is minimally invasive, but it is not risk-free and is not automatically safer or more effective than surgery, endoscopy, medicines, or observation for every patient. Technical success does not always produce symptom relief or cure disease, and repeat treatment or another approach may be needed. Suitability depends on anatomy, disease severity, comorbidities, imaging, local expertise, and the alternatives available.
Risks vary by procedure and may include pain, bleeding, infection, contrast reaction, kidney injury, radiation exposure, vessel or organ injury, clotting, device movement or blockage, sedation complications, treatment failure, and an unplanned operation or admission. Tissue sampling can be nondiagnostic and requires pathology; tumor treatments require oncology follow-up. The consent discussion should cover the patient-specific benefits, material risks, alternatives, and what happens if the procedure cannot be completed.
Preparation is individualized. Give the team a complete list of anticoagulants, antiplatelet drugs, diabetes medicines, supplements, allergies, kidney problems, pregnancy possibility, and prior contrast reactions. Do not stop a blood thinner or diabetes medicine on your own: the procedural team and prescribing clinician must balance bleeding against thrombosis or metabolic risk and provide exact written instructions. Fasting, laboratory tests, antibiotics, sedation, escort, admission, and aftercare differ by procedure.
Sources and summary
Sources and further reading
Conclusion
TACE can control selected liver tumors but is not curative for most patients and may require repeat treatment or another therapy. Post-embolization symptoms are common; liver failure, infection or abscess, biliary injury, kidney injury, nontarget embolization, and systemic drug effects can occur.